Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia Dec 7 Written by Mario Brkulj Mario Brkulj Previous Previous The era of in vivo T cell engineering Next Next Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia
Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia Dec 7 Written by Mario Brkulj Mario Brkulj
